Amylyx Pharmaceuticals Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization Application (MAA) for AMX0035 (taurursodiol]) regarding the treatment of adults with amyotrophic lateral sclerosis (ALS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following an oral explanation held at the . . . This content is for paid subscribers. Please click here …
Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution in the treatment of diseases. We expect to discover novel treatments capable of defeating cancers’ resistance to therapeutics old and new. We are following on all the firms that are discovering the unknown about life-threatening diseases, including the genetically derived diseases or else. Yesterday, May 25, 2023, we studied …
Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's ataxia (FA) - a rare genetic disease that causes difficulty walking, loss of sensation in the legs and arms . . . This content is for paid …
Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics aimed at treating progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). On May 19, 2023, Intercept Pharmaceuticals, announced that NASDAQ has halted trading of the company’s common stock. Today’s Meeting Today, the U.S. FDA Gastrointestinal Drugs Advisory …
Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for more than a quarter of all newly diagnosed cancer cases. Early detection is linked to improved survival rates, but typical screening recommendations — such as digital rectal exams or testing for the prostate specific antigen (PSA) biomarker — do not give the full picture. Halfway through 5-year study, ExoDx …
Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with dual targeting of the alarmin TSLP and stem cell factor (SCF), also known as KIT receptor ligand, developed from its bispecific antibody platform. TSLP and SCF demonstrated their contribution to the pathophysiology of various inflammatory, fibrotic and allergic disorders. The data . . . This content is for paid …
Longeveron in the NEWS On May 9, 2023, Longeveron (LGVN) announced new long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS). What is Hypoplastic Left Heart Syndrome HLHS is a rare and life-threatening congenital heart defect affecting approximately 1,000 babies per year. Infants born with HLHS have an underdeveloped or absent left ventricle. Current standard-of-care is …
CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology with more than 20 years of expertise in developing, optimizing and manufacturing this versatile biological molecule for medical purposes. CureVac’s proprietary technology uses optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable . . . This content is for paid …
Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for adults having chronic HDV and compensated liver disease, recommended granting full Marketing Authorization (MA) that . . . This content is for paid subscribers. …
May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social and Governance (ESG) areas of focus. John Leonard, M.D., Intellia President and Chief Executive Officer said, “As the leaders in a new era of medicine, we believe ESG principles support long-term value creation for …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
